Release Date: 2024-06-19

Radiotherapy As a Local Therapy in the Management of Patient with Oligometastatic Prostate Cancer

Ayberk Iplikci (Author), Ozgur Efiloglu (Author)

Release Date: 2024-06-19

Prostate cancer ranks as the second most common malignancy diagnosed among men worldwide. It manifest across a broad spectrum of presentations, ranging from localized low risk conditions to metastatic disease that is resistant to hormone therapy. Radiation therapy (RT) constitutes a significant therapeutic modality in the management of localized disease. While the use of RT [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page55
    Last Page67
    DOIhttps://doi.org/10.69860/nobel.9786053359142.5
    Page Count13
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Prostate cancer ranks as the second most common malignancy diagnosed among men worldwide. It manifest across a broad spectrum of presentations, ranging from localized low risk conditions to metastatic disease that is resistant to hormone therapy. Radiation therapy (RT) constitutes a significant therapeutic modality in the management of localized disease. While the use of RT in metastatic disease was previously quite limited, recent evidence demonstrates that RT can have positive effects beyond palliation, particularly in oligometastatic disease. Further research is needed to explore the systemic effects and immunological mechanisms of localized RT.

    Ayberk Iplikci (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0000-0002-5822-7799
    3Ayberk Iplikci was born in Istanbul, Turkey. He obtained his medical degree from the Istanbul University, Istanbul Faculty of Medicine and completed his urology residency at the Istanbul Medeniyet University. In 2024, he successfully completed the written and oral examinations of the “European Board of Urology” and earned the title of “Fellow of European Board of Urology”. His areas of interest include uro-oncology, urolithiasis and andrology.

    Ozgur Efiloglu (Author)
    MD, Associate Professor of Urology, Istanbul Medeniyet University
    https://orcid.org/0000-0003-4757-803X
    3Ozgur Efiloglu, an associate professor of urology at Istanbul Medeniyet University, has made significant contributions to the field since 2023. He completed his medical education at Istanbul University, Istanbul Medical Faculty, from 2001 to 2007. Following that, he pursued his residency in urology at Istanbul Goztepe Training and Research Hospital between 2011 and 2016. From 2016 to 2018, he worked at Sultanbeyli State Hospital, and from 2018 to 2023, he served as a urology specialist at Istanbul Medeniyet University. His areas of interest include andrology and incontinence. He has authored numerous international and national articles and book chapters. He is married and has two children.

    • Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol 2020;77(1):38–52.

    • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49.

    • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375(15):1415–24.

    • EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem, The Netherlands; 2024. Available from: https://d56bochluxqnz. cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf

    • Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol 2019;76(1):115–24.

    • Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J 2012;6(2):121–7.

    • Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, et al. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys 2022;114(4):684–92.

    • Orme JJ, Pagliaro LC, Quevedo JF, Park SS, Costello BA. Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist 2022;27(2):110–24.

    • Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Tria. Eur Urol 2019;75(3):410–8.

    • Baskar R, Dai J, Wenlong N, Yeo R, Yeoh K-W. Biological response of cancer cells to radiation treatment. Front Mol Biosci 2014;1:24.

    • Nguyen Q-N, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, et al. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 2013;119(18):3265–71.

    • Sujenthiran A, Nossiter J, Charman SC, Parry M, Dasgupta P, van der Meulen J, et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2017;99(5):1253–60.

    • Sterzing F, Münter MW, Schäfer M, Haering P, Rhein B, Thilmann C, et al. Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 2005;181(1):42–8.

    • Geinitz H, Roach III M, van As N, editors. Radiotherapy in Prostate Cancer [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. (Medical Radiology). Available from: https://link.springer.com/10.1007/978-3-642-37099-1

    • Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, et al. Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlenther Onkol 2020;196(5):421–43.

    • Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20(11):1531–43.

    • Bolla M, Mirimanoff R-O. Prostate cancer: On the road of progress. Asian J Urol 2019;6(2):123–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31061796

    • Makino T, Izumi K, Iwamoto H, Mizokami A. Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. Cancers (Basel) 2021;13(17).

    • Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13(1):8–10.

    • Farolfi A, Hadaschik B, Hamdy FC, Herrmann K, Hofman MS, Murphy DG, et al. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol 2021;4(5):714–30.

    • Savir-Baruch B, Choyke PL, Rowe SP, Schuster DM, Subramaniam RM, Jadvar H. Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2021;216(4):851–9.

    • Sutera P, Phillips RM, Deek M, Ozyigit G, Onal C, Tran PT. The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging. J Nucl Med 2022;63(3):339–41.

    • Imber BS, Varghese M, Goldman DA, Zhang Z, Gewanter R, Marciscano AE, et al. Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. Adv Radiat Oncol 2020;5(6):1213-24.

    • Rajwa P, Yanagisawa T, Gruber M, Heidenreich A, Joniau S, Briganti A, et al. Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-Review. Eur Urol Focus 2023;9(2):232–5.

    • Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 2015;68(2):325–34.

    • Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) 2018;392(10162):235366.

    • Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, et al. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. Eur Urol 2021;80(4):405–14.

    • Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2018;36(5):446– 53.

    • Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6(5):650–9.

    • Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. LongTerm Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol 2022;40(29):3377–82.

    • Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80(3):374–82.

    • Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw 2022;20(12):1288–98.

    • Nguyen PL, Alibhai SMH, Basaria S, D’Amico A V, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67(5):825–36.

    • Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol 2024;85(2):125–38.

    • Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, et al. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/ CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2021;27(23):6376–83.

    • Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol 2022;23(7):899–909.

    • Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol 2022;18(10):1185–98.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!